The prognostic impact of circulating tumor cells in subtypes of metastatic breast cancer.
Standard
The prognostic impact of circulating tumor cells in subtypes of metastatic breast cancer. / Wallwiener, Markus; Hartkopf, Andreas Daniel; Baccelli, Irène; Riethdorf, Sabine; Schott, Sarah; Pantel, Klaus; Marmé, Frederik; Sohn, Christof; Trumpp, Andreas; Rack, Brigitte; Aktas, Bahriye; Solomayer, Erich-Franz; Müller, Volkmar; Janni, Wolfgang; Schneeweiss, Andreas; Fehm, Tanja Natascha.
In: BREAST CANCER RES TR, Vol. 137, No. 2, 2, 2013, p. 503-510.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - The prognostic impact of circulating tumor cells in subtypes of metastatic breast cancer.
AU - Wallwiener, Markus
AU - Hartkopf, Andreas Daniel
AU - Baccelli, Irène
AU - Riethdorf, Sabine
AU - Schott, Sarah
AU - Pantel, Klaus
AU - Marmé, Frederik
AU - Sohn, Christof
AU - Trumpp, Andreas
AU - Rack, Brigitte
AU - Aktas, Bahriye
AU - Solomayer, Erich-Franz
AU - Müller, Volkmar
AU - Janni, Wolfgang
AU - Schneeweiss, Andreas
AU - Fehm, Tanja Natascha
PY - 2013
Y1 - 2013
N2 - The detection of circulating tumor cells (CTCs) in the peripheral blood of metastatic breast cancer (MBC) patients is an independent marker of prognosis. This large prospective multicenter study aimed to assess the impact of CTCs on overall survival (OS) and progression free survival (PFS) in patients with predefined molecular subgroups of MBC. To this end, 468 MBC patients were divided into three subgroups based on immunohistochemical staining of the primary tumor: (1) hormone receptor-positive/HER2-negative (HorR+/HER2-), (2) HER2-positive (HER2+), and (3) HorR-negative/HER2-negative (HorR-/HER2-) patients. CTC status (
AB - The detection of circulating tumor cells (CTCs) in the peripheral blood of metastatic breast cancer (MBC) patients is an independent marker of prognosis. This large prospective multicenter study aimed to assess the impact of CTCs on overall survival (OS) and progression free survival (PFS) in patients with predefined molecular subgroups of MBC. To this end, 468 MBC patients were divided into three subgroups based on immunohistochemical staining of the primary tumor: (1) hormone receptor-positive/HER2-negative (HorR+/HER2-), (2) HER2-positive (HER2+), and (3) HorR-negative/HER2-negative (HorR-/HER2-) patients. CTC status (
KW - Humans
KW - Female
KW - Middle Aged
KW - Multivariate Analysis
KW - Prospective Studies
KW - Prognosis
KW - Disease-Free Survival
KW - Tumor Markers, Biological/blood
KW - Receptor, erbB-2/metabolism
KW - Antineoplastic Agents/therapeutic use
KW - Receptors, Progesterone/metabolism
KW - Antibodies, Monoclonal, Humanized/therapeutic use
KW - Receptors, Estrogen/metabolism
KW - Neoplastic Cells, Circulating
KW - Breast Neoplasms/mortality/pathology/therapy
KW - Humans
KW - Female
KW - Middle Aged
KW - Multivariate Analysis
KW - Prospective Studies
KW - Prognosis
KW - Disease-Free Survival
KW - Tumor Markers, Biological/blood
KW - Receptor, erbB-2/metabolism
KW - Antineoplastic Agents/therapeutic use
KW - Receptors, Progesterone/metabolism
KW - Antibodies, Monoclonal, Humanized/therapeutic use
KW - Receptors, Estrogen/metabolism
KW - Neoplastic Cells, Circulating
KW - Breast Neoplasms/mortality/pathology/therapy
M3 - SCORING: Journal article
VL - 137
SP - 503
EP - 510
JO - BREAST CANCER RES TR
JF - BREAST CANCER RES TR
SN - 0167-6806
IS - 2
M1 - 2
ER -